Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple MyelomaJin Jie, Hong Ma, Xin Huang et al.|Blood|2019Cited by 40
Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple MyelomaSiguo Hao, Hong Ma, Jie Jin et al.|Blood|2020Cited by 36
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning RegimenLan Sun, Jianhua Feng, Na Wang et al.|Transplantation and Cellular Therapy|2019Cited by 27
Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell TherapyRujiao Dong, Kang Yu, Songfu Jiang et al.|Journal of Interferon & Cytokine Research|2021Cited by 16
CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cellsChongyun Xing, Jianhua Feng|Molecular Medicine Reports|2020Cited by 12